Clinical trial

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

NCT02659930

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention liposomal doxorubicin Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record pomalidomide Normalized identity: pomalidomideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2016-01-13

PhasePHASE1

Conditions

Kaposi Sarcomaverified · MONDO: Kaposi's sarcoma

Interventions

liposomal doxorubicinDRUG

pomalidomideDRUG · verified · RxNorm: pomalidomide

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

BethesdaMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02659930 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.